Advertisement
| chief business officer biotech: Science Lessons Gordon M. Binder, Philip Bashe, 2008 Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage. |
| chief business officer biotech: CEO John Decker, 2016-01-25 How does a good CEO deliver value? An ideal resource for all aspiring executives, this book provides a comprehensive portrait of the CEO's role and a clearly defined roadmap for acquiring the skill set of a successful CEO. There is a critical and growing need for effective and enlightened leadership in the private sector. The corporate world needs CEOs who can build companies, exceed customer expectations, address the needs of the world's growing population, and deliver superior value to investors. CEOs must balance on an incredibly difficult and challenging tightrope and apply a daunting range of skills and experience at the highest levels to do so. Over one third of all new CEOs are out within three years and many companies don't achieve their full potential due to lack of leadership talent. CEO: Mastering the Corporate Pyramid shines a spotlight on what CEOs actually do, identifies the skills necessary to do the job, and explains how to develop these skills for anyone aspiring to the executive suite as well as those considering starting or buying a business. It supplies a unique and powerful roadmap for career success and increases the chances for an aspiring CEO to make it to the top and survive and thrive in the position. |
| chief business officer biotech: Plunkett's Biotech & Genetics Industry Almanac Jack W. Plunkett, 2008-09 A complete market research guide to the business of biotech, genetics, proteomics and related services--a tool for strategic planning, competitive intelligence, employment searches, or financial research. Complete profiles of nearly 400 leading biotech companies, in-depth chapters on trends. Includes glossary thorough indexes, statistics, research and development, emerging technology--as well a addresses, phone numbers, and executive names. |
| chief business officer biotech: The Biotech Business Handbook Michael G. Pappas, 2012-12-06 One comment often repeated to me by coworkers in the biotechnology industry deals with their frustration at not understanding how their particular roles fit into their company's overall scheme for developing, manufacturing, and marketing biomedical products. Although these workers know their fields of specialty and responsibilities very well, whether it be in product research and development, regulatory affairs, manufacturing, packaging, quality control, or marketing and sales, they for the most part lack an understanding of precisely how their own contributory pieces fit into the overall scheme of the corporate biotechnology puzzle. The Biotech Business Handbook was written to assist the biotechnologist-whether a tech nician, senior scientist, manager, marketing representative, or college student interested in entering the field-in building a practical knowledge base of the rapidly expanding and maturing biotechnology segment of the healthcare industry. Because biotechnology in the United States and abroad covers many disciplines, much of the information presented in this book deals with the biomedical diagnostic aspects of the industry. Business subjects for the most part unfamiliar to technically oriented people, such as the types of biotechnology corpo rations, their business and corporate structures, their financing, patent, and trademark mat ters, their special legal issues, and the contributions of their consultants are treated in a manner designed to make them clear and understandable. |
| chief business officer biotech: Plunkett's Biotech & Genetics Industry Almanac 2006: The Only Complete Reference to the Business of Biotechnology and Genetic Engineering Plunkett Research, Ltd, 2005 A complete guide to the business of biotech, genetics, proteomics and related services. Complete profiles of nearly 450 leading biotech companies, in-depth chapters on trends. Includes glossary thorough indexes, statistics, research and development, emerging technology. |
| chief business officer biotech: The Business of Bioscience Craig D. Shimasaki, 2009-09-18 My journey into this fascinating field of biotechnology started about 26 years ago at a small biotechnology company in South San Francisco called Genentech. I was very fortunate to work for the company that begat the biotech industry during its formative years. This experience established a solid foundation from which I could grow in both the science and business of biotechnology. After my fourth year of working on Oyster Point Boulevard, a close friend and colleague left Genentech to join a start-up biotechnology company. Later, he approached me to leave and join him in of all places – Oklahoma. He persisted for at least a year before I seriously considered his proposal. After listening to their plans, the opportunity suddenly became more and more intriguing. Finally, I took the plunge and joined this ent- preneurial team in cofounding and growing a start-up biotechnology company. Making that fateful decision to leave the security of a larger company was extremely difficult, but it turned out to be the beginning of an entrepreneurial career that forever changed how I viewed the biotechnology industry. Since that time, I have been fortunate to have cofounded two other biotechnology com- nies and even participated in taking one of them public. During my career in these start-ups, I held a variety of positions, from directing the science, operations, regulatory, and marketing components, to subsequently becoming CEO. |
| chief business officer biotech: Purpose & Impact Anita Hoffmann, 2018-04-17 Purpose & Impact is the first book to provide guidance to senior executives and professionals on how to rethink and even relaunch their careers in ways that align with wider purpose and societal impact. With our increasing longevity, the concept of retirement is becoming redundant; executives need, financially, and want, motivationally, to continue to work well beyond what is currently considered ‘retirement age’. At around age 50, when we often leave our mainstream employers, we could be looking forward to around another 30 healthy years, equivalent to a whole second career. This book sets out a topic that is becoming increasingly important and urgent for governments, companies and executives alike. Purpose & Impact is underpinned by extensive research, including interviews with over 90 senior executives. Many of their stories are included within the book and provide the reader with real insight into how very diverse senior executives and professionals have created roles that have enabled their own personal growth and development and had positive impacts on wider society. In addition, helpful tools and guides are used throughout the book to help the reader in their decision-making processes during the different stages of discovering and developing themselves and their career goals. |
| chief business officer biotech: Building Biotechnology Yali Friedman, 2006 Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, political, regulatory, and commercial factors that drive the biotechnology industry: * Cultivate a career in biotechnology, with or without an MBA or Ph.D. * Fund and assemble a company * Manage research and development, alliances, and funding * Understand the diverse factors defining the biotechnology industry * Invest intelligently in biotechnology This second edition significantly expands upon the foundation laid by the first, updating recent developments and adding significantly more case studies, informative figures and tables. |
| chief business officer biotech: The importance of the biotechnology industry and venture capital support in innovation United States. Congress. House. Committee on Small Business. Subcommittee on Rural Enterprises, Agriculture, and Technology, 2005 |
| chief business officer biotech: Désiré Collen - Biotech Pioneer Paul Huybrechts, Frieda Van Wijck, 2020-08-27 Désiré Collen, Biotech Pioneer relates the fascinating story of scientific discovery in a time when biotechnology was not yet a science. Although the cultivation and cross fertilization of plants were, strictly speaking, biotechnological techniques, modern biotechnology dates from the early 1970s, when pioneers such as biochemist Herbert Boyer from the university of California managed to transfer genetic material into a bacterium. Together with venture capitalist Robert Swanson, Boyer set up Genentech, one of the first genetic engineering companies. Just a few years later, on the other side of the Atlantic, in Leuven, Désiré Collen discovered t-PA, the enzyme responsible for fibrinolysis, or the dissolving of blood clots. Clogged arteries were then still one of the major causes of death. The ensuing cooperation between Collen and Genentech was the beginning of a long-lasting success story, from which not only Collen but also scientific research and the University of Leuven benefitted greatly for many years. According to a Reuters ranking, KU Leuven has been, from 2016 onwards, the most innovative university in Europe. Flanders and Belgium served as the cradle of several highly successful biotech companies. t-PA was a relatively expensive medicine, and Collen went on to develop a much cheaper clot-dissolving remedy to benefit patients in less affluent countries. He failed, however, to find the necessary finances for Phase 3 trials. Meanwhile, he had set up ThromboGenics, a company which later specialized in ophthalmology. Collen continued to stimulate and finance research in other fields, such as the cardiovascular research of Peter Carmeliet. In 2013 he left ThromboGenics, following a difference in views on the company’s focus, and in 2015 he set up Fund+, a biotech-oriented investment firm. Fund+ has meanwhile acquired a prominent place among European biotech investment funds and has scored some astonishing early successes. In June 2020, Fund+ had 13 companies in its portfolio, with several more waiting to come on board. |
| chief business officer biotech: BioIndustry Ethics David L. Finegold, Cecile M Bensimon, Abdallah S. Daar, Margaret L. Eaton, Beatrice Godard, Bartha Maria Knoppers, Jocelyn Mackie, Peter A. Singer, 2005-07-19 This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics. |
| chief business officer biotech: Business Development for the Biotechnology and Pharmaceutical Industry Mr Martin Austin, 2012-09-28 Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world. |
| chief business officer biotech: Healthcare Biotechnology Dimitris Dogramatzis, 2016-04-19 Foreseeing and planning for all of the possibilities and pitfalls involved in bringing a biotechnology innovation from inception to widespread therapeutic use takes strong managerial skills and a solid grounding in biopharmaceutical research and development procedures. Unfortunately there has been a dearth of resources for this aspect of the field. |
| chief business officer biotech: Biotechnology Entrepreneurship Craig Shimasaki, 2014-04-08 As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a 'how-to' for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. - Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars - Case studies are interspersed throughout each chapter to support key concepts and best practices. - Enhanced by use of numerous detailed graphics, tables and flow charts |
| chief business officer biotech: A Biotech Manager's Handbook M O'Neill, M M Hopkins, 2012-05-02 A biotech manager's handbook lays out - in a simple, straightforward manner - for the manager or would-be entrepreneur the basic principles of running a biotech company. Most managers in biotechnology companies are working in their first company or in their first managerial role. Their expertise and experience in the scientific part of the work can be taken as a given but there is a whole range of other skills to be learned and areas of expertise to come to terms with. Small companies do not have big budgets to hire people or time to become an expert in so many areas. The book starts by outlining the state of the biopharmaceutical industry and goes on to explain the importance of planning (no matter what the size of the company). Succeeding chapters deal with the basics of intellectual property, perspectives from a university technology transfer office and how to raise some initial funding from an investor and entrepreneur. - No other 'how to' manual exists for this sector - Written by a range of expert professionals in each area, all in one book - Is the only 'bench to bedside' book covering the whole spectrum of development |
| chief business officer biotech: Plunkett's Biotech & Genetics Industry Almanac 2008: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies Jack W. Plunkett, 2007-09 A market research guide to the business of biotech, genetics, proteomics and related services. It offers tools for strategic planning, competitive intelligence, employment searches, or financial research. It features profiles of nearly 400 leading biotech companies and includes chapters on trends. |
| chief business officer biotech: Biotechnology in the Time of COVID-19 Jeremy M. Levin, 2020-05-31 47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity. |
| chief business officer biotech: Plunkett's Biotech & Genetics Industry Almanac 2007: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies Plunkett Research Ltd, Jack W. Plunkett, 2006-09 Presents a market research guide to the business of biotech, genetics, proteomics and related services - a tool for strategic planning, competitive intelligence, employment searches, or financial research. This title provides profiles of over 400 biotech companies and in-depth chapters on trends. |
| chief business officer biotech: The Role of Small Business in Innovation and Job Creation United States. Congress. House. Committee on Science, Space, and Technology (2011). Subcommittee on Technology and Innovation, 2011 |
| chief business officer biotech: Biotech Industry Bryan P. Bergeron, Paul Chan, 2004-01-30 Publisher Description |
| chief business officer biotech: BioScan , 2009 |
| chief business officer biotech: The Business of Healthcare Innovation Lawton Robert Burns, 2020-03-12 Updated third edition of the authoritative textbook on business models and trends in the tech sectors of the healthcare industry. |
| chief business officer biotech: Biotechnology Entrepreneurship Craig Shimasaki, 2020-05-16 This second edition of Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies is an authoritative, easy-to-read guide covering biotechnology entrepreneurship and the process of commercializing innovative biotechnology products. This best practice resource is for professional training programs, individuals starting a biotech venture, and for managers and experienced practitioners leading biotech enterprises. It is a valuable resource for those working at any level in the biotech industry, and for professionals who support and provide essential resources and services to the biotech industry. This practical, how-to book is written by seasoned veterans experienced in each of the operational functions essential for starting, managing, and leading a successful biotech company.Biotechnology Entrepreneurship explains the biotech business components and underlying strategies, interspersed with practical lessons from successful biotech entrepreneurs, educators, and experienced practitioners. These veteran contributors share their insights on how to be successful in this challenging but exciting industry. Subjects range from technology licensing and translating an idea into a viable business, forming your legal company entity, securing angel and venture capital, navigating product development, FDA regulatory approval, and biomanufacturing.This book is a user-friendly guide to decision-making and overall strategy written as a hands-on management tool for leaders and managers of these dynamic biotechnology ventures. If you are contemplating starting a biotech company, are a manager at any level, a seasoned veteran, or service provider in the biotech industry, this book is a must read.This second edition includes several new chapters on topics such as: - What you need to know about valuation and term sheets - Investor presentations and what you need in a biotech investor pitch deck - Mentorship and why you need mentors - Artificial intelligence applications in biotech and pharma - Common biotech entrepreneur mistakes and how to avoid them |
| chief business officer biotech: Handbook of Research on Techno-Entrepreneurship, Second Edition François Thérin, 2014-01-31 With chapters focusing on China, India, Southeast Asia and South America, the Handbook explores views on the new hot spots in techno-entrepreneurship development. |
| chief business officer biotech: The Report , 2007 |
| chief business officer biotech: Genetic Engineering & Biotechnology News , 2009 |
| chief business officer biotech: Financing the Entrepreneurial Venture Paul A. Gompers, 2024-05-14 Financing the Entrepreneurial Venture focuses on financial management within entrepreneurial firms. Most of these are young firms, although some are more established. The book examines these firms at all phases of their life cycle, from the initial idea generation to the ultimate harvesting of the venture. The book covers firms in a diverse set of industries including high technology, low technology and services. A significant fraction of the cases focus on non-U.S. ventures. Additionally, the issues of gender and diversity are addressed in a number of settings. |
| chief business officer biotech: The Long Shot Kate Bingham, Tim Hames, 2022-10-20 How Covid-19 vaccines went from the laboratory to people’s arms – the inside story of an extraordinary national campaign against all odds A Sunday Times bestseller and Financial Times Book of the Year. The unmissable inside story of the race against the virus. Catapulted into an international crisis, Kate Bingham knew the odds were heavily stacked against a workable Covid-19 vaccine. From a remote cottage, Bingham juggled vaccine suppliers, Whitehall, the media circus… as deaths mounted and the world shut down. Political manoeuvring, miscommunications and administrative meddling nearly jeopardised the project. But perseverance and expertise paid off. Bingham’s eclectic team secured the first vaccine doses administered in the West, saving thousands of lives in the UK as new variants struck. Now, nearly every adult in Britain has had the jab, lockdowns have ended and we can finally live with Covid. This is the insider view into how the Vaccine Taskforce beat those long odds and delivered a scientific miracle. |
| chief business officer biotech: Strategic Alliances as Social Facts Mark De Rond, 2003-06-19 How can we explain a proliferation of alliances when the probability of failure is higher than success? And why have we emphasized their order, manageability and predictability whilst acknowledging that they tend to be experienced as messy, politically charged and unpredictable? Mark de Rond, in this provocative book, sets out to address such paradoxes. Based on in-depth case studies of three major biotechnology alliances, he suggests that we need theories to explain idiosyncracy as well as social order. He argues that such theories must allow for social conduct to be active and self-directed but simultaneously inert and constrained, thus permitting voluntarism, determinism, and serendipity alike to explain causation in alliance life. The book offers a highly original combination of insights from social theory and intellectual history with more mainstream strategic management and organizations literature. It is a refreshing and thought-provoking analysis that will appeal to practitioner and academic researcher alike. |
| chief business officer biotech: Subcommittee on Healthcare & Technology United States. Congress. House. Committee on Small Business. Subcommittee on Healthcare and Technology, 2011 |
| chief business officer biotech: Biotechnology - The Science and the Business Derek G. Springham, Vivian Moses, Ronald E. Cape, 2020-08-18 Biotechnology has not stood still since 1991 when the first edition of Biotechnology - The Science and the Business was published. It was the first book to treat the science and business of technology as an integrated subject and was well received by both students and business professionals. All chapters in this second edition have been updated and revised and some new chapters have been introduced, including one on the use of molecular genetic techniques in forensic science. Experts in the field discuss a range of biotechnologies, including pesticides, the flavor and fragrance industry, oil production, fermentation and protein engineering. On the business side, subjects include managing, financing, and regulation of biotechnology. Some knowledge of the science behind the technologies is assumed, as well as a layperson's view of buying and selling. As with the first edition, it is expected that this book will be of interest to biotechnology undergraduates, postgraduates and those working in the industry, along with students of business, economics, intellectual property law and communications. |
| chief business officer biotech: Plunkett's E-Commerce and Internet Business Almanac 2007 Jack W. Plunkett, 2007-02 Serves as a guide to the E-Commerce and Internet Business worldwide. This volume features data you need on E-Commerce and Internet Industries, including: E-Commerce statistics and trends; Internet research and development; Internet growth companies; online services and markets; online retailing strategies; and more. |
| chief business officer biotech: Corporate Governance and Initial Public Offerings Alessandro Zattoni, William Judge, 2012-03-22 A major international study on corporate governance and Initial Public Offerings (IPOs) in twenty-one countries. |
| chief business officer biotech: Juvenescence Jim Mellon, Al Chalabi, 2017-09-25 |
| chief business officer biotech: Business Development for the Biotechnology and Pharmaceutical Industry Martin Austin, 2016-04-08 Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world. |
| chief business officer biotech: Pharmaceutical Industry Guide Institute for Biotechnology Information (North Carolina Biotechnology Center), 1997 |
| chief business officer biotech: Plunkett's Consulting Industry Almanac 2007: Consulting Industry Market Research, Statistics, Trends & Leading Companies Jack W. Plunkett, Plunkett Research Ltd, 2007-06 Covers trends in consulting in such fields as marketing, information technology, management, logistics, supply chain, manufacturing and health care. This guide contains contacts for business and industry leaders, industry associations, Internet sites and other resources. It also includes statistical tables, an industry glossary and indexes. |
| chief business officer biotech: Pervasive Collaborative Networks Luis M. Camarinha-Matos, Willy Picard, 2008-08-27 COLLABORATIVE NETWORKS Becoming a pervasive paradigm In recent years the area of collaborative networks is being consolidated as a new discipline (Camarinha-Matos, Afsarmanesh, 2005) that encompasses and gives more structured support to a large diversity of collaboration forms. In terms of applications, besides the “traditional” sectors represented by the advanced supply chains, virtual enterprises, virtual organizations, virtual teams, and their breading environments, new forms of collaborative structures are emerging in all sectors of the society. Examples can be found in e-government, intelligent transportation systems, collaborative virtual laboratories, agribusiness, elderly care, silver economy, etc. In some cases those developments tend to adopt a terminology that is specific of that domain; often the involved actors in a given domain are not fully aware of the developments in the mainstream research on collaborative networks. For instance, the grid community adopted the term “virtual organization” but focused mainly on the resource sharing perspective, ignoring most of the other aspects involved in collaboration. The European enterprise interoperability community, which was initially focused on the intra-enterprise aspects, is moving towards inter-enterprise collaboration. Collaborative networks are thus becoming a pervasive paradigm giving basis to new socio-organizational structures. |
| chief business officer biotech: Plunkett's E-Commerce & Internet Business Almanac 2008: E-Commerce & Internet Business Industry Market Research, Statistics, Trends & Leading Companie Plunkett Research Ltd, 2007-03 This new almanac will be your ready-reference guide to the E-Commerce & Internet Business worldwide! In one carefully-researched volume, you'll get all of the data you need on E-Commerce & Internet Industries, including: complete E-Commerce statistics and trends; Internet research and development; Internet growth companies; online services and markets; bricks & clicks and other online retailing strategies; emerging e-commerce technologies; Internet and World Wide Web usage trends; PLUS, in-depth profiles of over 400 E-Commerce & Internet companies: our own unique list of companies that are the leaders in this field. Here you'll find complete profiles of the hot companies that are making news today, the largest, most successful corporations in all facets of the E-Commerce Business, from online retailers, to manufacturers of software and equipment for Internet communications, to Internet services providers and much more. Our corporate profiles include executive contacts, growth plans, financial records, address, phone, fax, and much more. This innovative book offers unique information, all indexed and cross-indexed. Our industry analysis section covers business to consumer, business to business, online financial services, and technologies as well as Internet access and usage trends. The book includes numerous statistical tables covering such topics as e-commerce revenues, access trends, global Internet users, etc. Purchasers of either the book or PDF version can receive a free copy of the company profiles database on CD-ROM, enabling key word search and export of key information, addresses, phone numbers and executive names with titles for every company profiled. |
| chief business officer biotech: The 5-STAR Business Network: And The CEOs Who Are Building The Next Generation Of Super Corporations With It Vivek Sood, 2013-04-17 If you are as deeply passionate about the world of business and supply chain networks as I am, and enjoy exploring similar questions, and coming up with answers that will help immensely in using this wisdom to build your business, then join me. This book is a journey of exploration through the world of business networks that run the commercial world today. When General Motors filed for Chapter XI protection in 2008, it also marked the closing of a chapter in modern commerce. General Motors was seen as the paragon of modern American management theory as popularized by Peter Drucker in the middle of the 20th century. It was at this venerable company that Drucker formed his early thoughts about management as a profession, separation of the ownership from management of enterprise, the key functions of management, division of labour, theory of leadership of enterprise, indeed the very concept of the corporation. His writings filled the needs of the time, and were picked up by Ivy League business schools and corporations alike to form the basic foundation of management profession. Indeed there was a time when General Motors and US commerce were thought of as interchangeable entities with the popular aphorism that what is good for GM is good for America and vice versa. Some people still think this is the case. They see the decline of General Motors as symptomatic of a wider malaise in the US economy. Others think that General Motors will rise like a phoenix to become an industrial powerhouse. While we do not know what will eventually happen to General Motors, we know that new models of commerce, new industries, new technologies and new ways of solving old problems will be required to build a stronger economy at a global level. All of these will not necessarily come out of one country, one continent or even one region. It is not a surprise that the established minds find it difficult to think outside the box. Since the times of Aristotle, Socrates and perhaps even before that, new ideas must come from new places - from outside the established order of thinking. No wonder then that the most innovative companies in the US still choose to locate on the West Coast. Many of the most successful corporations were formed by college drop outs and the most successful business models do not even have names yet. In this book, we will not only name some of these models, but we also will study them closely and understand these new methods. Most effective business leaders know: * Why did Apple sue Samsung while it continues to buy critical parts for its winning products from Samsung? * Why did Google create Android OS for mobile applications, and is now talking about opening its own retail stores? * Why did Amazon create Kindle when the market is already saturated by other tablets and similar products? * How did Nokia mobile phone lose its shine? * Why did Apple build its own retail presence? * How will shale gas discoveries in North America change the business world and perhaps the geo-political balance in the next 10 years? Do you? Win big time by using the wisdom of your business networks to create, innovate, deliver and profit. Read this book to find out how. More details of the book on http://5starbusinessnetwork.com/ |
Job Description Chief Business Officer - Firalis Molecular …
As the CBO, you will be responsible for driving the overall business strategy and growth of our organization. You will collaborate with the CEO to develop and implement strategic initiatives, …
Press Release - glycoera.com
GlycoEra also announced the addition of industry veteran Greg Fralish, Ph.D., as Chief Business Officer to expand and strengthen its leadership team. “Adding BMS as an investor further …
Domain Therapeutics further strengthens leadership team …
appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team. In his new position, Sean will lead corporate strategy and …
Curriculum Vitae | Susan Dexter - Sartorius
Sonnet Biotherapeutics, Inc., United States, Chief Technical Officer | Non-clinical | CMC | Supply Chain. Responsible for product development for Sonnet’s pipeline of biotherapeutic cytokine …
Our business development team - Organon
Biotech, Inc. (2696.HK) to license commercialization rights for biosimilar candidates referencing PERJETA® (pertuzumab, HLX11) and PROLIA®/XGEVA® (denosumab, HLX14). …
Executive Compensation & Team Composition:
Feb 3, 2017 · Chief Business Officer Primary charter of the CBO role is to be in charge of the BD strategy, partnering, in‐and out‐ licensing, collaboration agreements, non‐dilutive financing, …
Dr. Ron Newbold Business & Industry Vice President Strategic …
biotech companies. After graduating from the University of Rochester and a postdoctoral fellowship in Organic Chemistry with Nobel Laureate E.J. Corey at Harvard University, he …
Trinity Biotech Appoints Global Life Sciences Leader as Chief ...
DUBLIN, Ireland (September 3, 2024) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, …
CHIEF OPERATING OFFICER - biomapas.eu
The Chief Operating Officer (COO) is responsible for management day-to-day activities and operation of the business. The COO reports directly to the Chief Executive Officer (CEO).
Chief Business Officer Biotech (Download Only)
research guide to the business of biotech, genetics, proteomics and related services--a tool for strategic planning, competitive intelligence, employment searches, or financial research. …
OncoOne Appoints Brent Meadows as Chief Business Officer
Vienna, Austria – September 15, 2021 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and other indications, announced today the …
ChiefExecutiveOfficer - BioTalent Canada
Learn more about the role of CEO by downloading the full skills profile for free at www.biotalent.ca/profiles. Biotechnology’s fusion of science and business creates unique …
Executive Team - American Society for Radiation Oncology
Thorsten Melcher, Ph.D., joined RefleXion in July 2019 as chief business officer with over 25 years of experience in biotechnology and pharmaceutical business development. Most …
Chief Development Officer - Immunostherapy
A key member of the Executive Management Team, the Chief Development Officer (CDO) will develop and lead ImmunOs Therapeutics’ Research and Development strategy while …
Blumberg Institute launches MERLIN Biotech, a spinout …
Louis P. Kassa, III, MPA, MERLIN Biotech chief business officer, is executive vice president and chief operating officer of the Pennsylvania Biotechnology Center, one of the nation’s most …
Lycia Therapeutics Strengthens Leadership Team with …
Other members of Lycia’s leadership team include Christian Hofmann, Ph.D., Chief Business Officer, who joined Lycia from the Partnering group with Roche/Genentech; Jason Lewis, …
Vor Biopharma Appoints Veteran Biotech Executive Dr. Robert …
Dr. Ang is the former Chief Business Officer of Neon Therapeutics, part of the early team establishing the company prior to its Series A investment and through its initial public offering. …
International Biotechnology Symposium Explores the Business …
Steve Xanthoudakis, Chief Business Officer, CQDM Since its inception in 2008, CQDM, a non-profit biopharmaceutical research consortium and an industrial research cluster, has been …
CureVac Chief Technology Officer to Pursue New Career …
Jan 17, 2022 · TÜBINGEN, Germany/ BOSTON, USA – January 17, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of …
CMO Success Blueprint: Timing, Talent, and Retention in Early …
We examined the historical Chief Medical Officer (CMO) hiring timelines across thirty early-stage biotech organizations – collecting data on their first CMO hire and their sitting CMO. Data …
Job Description Chief Business Of…
As the CBO, you will be responsible for driving the overall business strategy …
Press Release - glycoera.com
GlycoEra also announced the addition of industry veteran Greg Fralish, Ph.D., as Chief Business Officer to expand …
Domain Therapeutics further strengthen…
appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive …
Curriculum Vitae | Susan Dexter - Sar…
Sonnet Biotherapeutics, Inc., United States, Chief Technical Officer | Non-clinical | CMC | Supply Chain. Responsible …
Our business development tea…
Biotech, Inc. (2696.HK) to license commercialization rights for biosimilar candidates referencing …
